|
KMID : 1040120160020010005
|
|
Evidence and Values in Healthcare
2016 Volume.2 No. 1 p.5 ~ p.10
|
|
|
Conditional approval system of health technology
|
|
이월숙:Lee Worl-Sook
저자없음:No authors listed
|
|
|
Abstract
|
|
|
Conditional approval system of health technology’ is a support program for promising research phase technology that didn’t accept new health technology in Korea. If it makes a new medical technology assessment is insufficient evidence to determine the safety and effectiveness can not be introduced in the health care market. ‘Conditional approval system of health technology’ was introduced in 2014, for promising medical technologies that have clinical benefit at the national
level. Foreign countries that perform evidence-based health technology assessments to determine the insurance coverage
of health technology have similar systems such as the ‘Coverage with Evidence Development’ of United States, ‘Only In
Research’ of United Kingdom, ‘Conditionally Funded Field Evaluation’ of Canada. ‘Conditional approval system of health
technology’ is currently being conducted in ten hospitals for three medical technology (Therapeutic Use of Autologous
Peripheral Blood Stem Cell in Myocardial Infarction, Autologous Platelet Rich Plasma Application, Irreversible Electroporation for Pancreatic Cancer). ‘Conditional approval system of health technology’ is expected to greatly contribute to determine the safety and efficacy through the generated evidences in the real world. Therefore, it requires the continued
attention and cooperation for the development of the ‘Conditional approval system of health technology’.
|
|
|
KEYWORD
|
|
|
Healthcare technology assessment, Conditional approval system of health technology, Evidence development
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|